Shopping Cart 0
Cart Subtotal
USD 0

Refractory Multiple Myeloma Global Clinical Trials Review, H1, 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 5000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 7500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Refractory Multiple Myeloma Global Clinical Trials Review, H1, 2018

Summary

GlobalData's clinical trial report, Refractory Multiple Myeloma Global Clinical Trials Review, H1, 2018" provides an overview of Refractory Multiple Myeloma clinical trials scenario. This report provides top line data relating to the clinical trials on Refractory Multiple Myeloma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape

- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

- The Report provides enrollment trends for the past five years

- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment

- Helps in identifying prominent locations for conducting clinical trials which saves time and cost

- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

- Supports understanding of trials count and enrollment trends by country in global therapeutics market

- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Report Guidance 6

GlobalData Clinical Trials Report Coverage 7

Clinical Trials by Region 8

Clinical Trials and Average Enrollment by Country 9

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11

Top Five Countries Contributing to Clinical Trials in Europe 12

Top Countries Contributing to Clinical Trials in North America 13

Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14

Top Five Countries Contributing to Clinical Trials in Central and South America 15

Clinical Trials by G7 Countries: Proportion of Refractory Multiple Myeloma to Oncology Clinical Trials 16

Clinical Trials by Phase in G7 Countries 17

Clinical Trials in G7 Countries by Trial Status 18

Clinical Trials by E7 Countries: Proportion of Refractory Multiple Myeloma to Oncology Clinical Trials 19

Clinical Trials by Phase in E7 Countries 20

Clinical Trials in E7 Countries by Trial Status 21

Clinical Trials by Phase 22

In Progress Trials by Phase 23

Clinical Trials by Trial Status 24

Clinical Trials by End Point Status 25

Subjects Recruited Over a Period of Time 26

Clinical Trials by Sponsor Type 27

Prominent Sponsors 28

Top Companies Participating in Refractory Multiple Myeloma Therapeutics Clinical Trials 29

Prominent Drugs 30

Latest Clinical Trials News on Refractory Multiple Myeloma 31

Jun 17, 2018: Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone Reduces the Risk of Disease Progression by 46% Versus Pomalidomide/Dexamethasone Alone in Patients with Relapsed or Refractory Multiple Myeloma 31

Jun 15, 2018: Molecular Partners presents updated results from its ongoing Phase 2 combination study of its lead oncology drug MP0250 at EHA in Stockholm 31

Jun 15, 2018: Update on bb2121, a Promising Therapy for Patients with Heavily Pre-treated Relapsed/Refractory Multiple Myeloma 32

Jun 11, 2018: FDA Approves Addition Of Positive Overall Survival Data From Phase 3 ASPIRE Trial To KYPROLIS (carfilzomib) Label 32

Jun 01, 2018: Updated Results of Ongoing Multicenter Phase I Study of bb2121 anti-BCMA CAR T Cell Therapy Continue to Demonstrate Deep and Durable Responses in Patients with Late-Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting 33

Jun 01, 2018: Phase 3 A.R.R.O.W. Interim Analysis Shows Once-Weekly 70 mg/m2 KYPROLIS (carfilzomib) Regimen Significantly Extended Progression-Free Survival Versus A Twice-Weekly 27 mg/m2 Regimen In Patients With Relapsed And Refractory Multiple Myeloma 34

Jun 01, 2018: Results of Phase III OPTIMISMM Study Presented at ASCO 2018 Showed the PVd Triplet Improved PFS in Early Lines of Relapsed or Refractory Multiple Myeloma 34

May 25, 2018: Glenmark Pharmaceuticals Announces Poster Presentation on GBR 1342 at 2018 ASCO Annual Meeting 35

May 17, 2018: PharmaMar Announces Data Presentations on its molecule Plitidepsin at ASCO 2018 35

May 17, 2018: bluebird bio to Present New Data from LentiGlobin Transfusion-Dependent -Thalassemia and Severe Sickle Cell Disease Clinical Studies at Annual Congress of the European Hematology Association 35

May 17, 2018: Genmab Announces Abstracts to be Presented on Daratumumab at 23rd EHA Annual Congress 36

May 17, 2018: Karyopharm to Present Selinexor Phase 1b/2 STOMP Data at the European Hematology Association 2018 Annual Meeting 36

May 16, 2018: Molecular Partners to present final MP0250 Phase 1 data at ASCO Annual Meeting 2018 37

May 16, 2018: bluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting 37

May 16, 2018: Janssen to Present Data on DARZALEX at ASCO 2018 38

May 16, 2018: Celgene to Present New Clinical Data in Blood Cancer and Solid Tumor Therapies at Upcoming American Society of Clinical Oncology (ASCO) Scientific Sessions 39

Apr 30, 2018: Amgen Receives Positive CHMP Opinion To Add Overall Survival Results From The Phase 3 ASPIRE Study To KYPROLIS (carfilzomib) Label 39

Apr 28, 2018: BMS Phase 2 trial of the efficacy and safety of Elotuzumab 40

Apr 28, 2018: BMS Phase 2 single arm study of safety of Elotuzumab 40

Apr 25, 2018: Genmab to Present Data on Daratumumab at 2018 ASCO Annual Meeting 40

Apr 25, 2018: Incyte to Present Data from Phase 1 Study of Ruxolitinib at the 2018 ASCO Annual Meeting 40

Apr 21, 2018: Molecular Partners presented preliminary results from the ongoing phase 2 study of MP0250 at the European Myeloma Network Meeting in Turin 41

Apr 18, 2018: Trillium Therapeutics Reports TTI-622 Preclinical Data at the 2018 AACR Annual Meeting 41

Apr 17, 2018: Poseida Announces Initial Phase 1 Data for P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple Myeloma 41

Apr 05, 2018: Sorrento and Celularity to Start Anti-CD38 CAR-T Phase 1 Clinical Trial in Patients With Relapsed or Refractory Multiple Myeloma 42

Clinical Trial Profile Snapshots 43

Appendix 487

Abbreviations 487

Definitions 487

Research Methodology 488

Secondary Research 488

About GlobalData 489

Contact Us 489

Disclaimer 489

Source 490


List Of Figure

List of Figures

Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials by Region (%), 2018* 8

Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9

Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10

Refractory Multiple Myeloma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 11

Refractory Multiple Myeloma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 12

Refractory Multiple Myeloma Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 13

Refractory Multiple Myeloma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018* 14

Refractory Multiple Myeloma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018* 15

Proportion of Refractory Multiple Myeloma to Oncology Clinical Trials, G7 Countries (%), 2018* 16

Refractory Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17

Refractory Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 18

Proportion of Refractory Multiple Myeloma to Oncology Clinical Trials, E7 Countries (%), 2018* 19

Refractory Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 20

Refractory Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 21

Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials by Phase (%), 2018* 22

Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 23

Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials by Trial Status, 2018* 24

Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, by End Point Status, 2018* 25

Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 26

Refractory Multiple Myeloma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 27

Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 28

Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 29

Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 30

GlobalData Methodology 488


List Of Table

List of Tables

Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials by Region, 2018* 8

Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9

Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10

Refractory Multiple Myeloma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 11

Refractory Multiple Myeloma Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 12

Refractory Multiple Myeloma Therapeutics Clinical Trials, North America, Top Countries, 2018* 13

Refractory Multiple Myeloma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018* 14

Refractory Multiple Myeloma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018* 15

Proportion of Refractory Multiple Myeloma to Oncology Clinical Trials, G7 Countries (%), 2018* 16

Refractory Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17

Refractory Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 18

Proportion of Refractory Multiple Myeloma to Oncology Clinical Trials, E7 Countries (%), 2018* 19

Refractory Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 20

Refractory Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 21

Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials by Phase, 2018* 22

Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 23

Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials by Trial Status, 2018* 24

Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, by End Point Status, 2018* 25

Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 26

Refractory Multiple Myeloma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 27

Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 28

Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 29

Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 30

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Refractory Multiple Myeloma Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO's, Terminated, Suspended and Withdrawn trials of Refractory Multiple Myeloma, Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania


Companies

Celgene Corp

Johnson & Johnson

Amgen Inc

Takeda Pharmaceutical Co Ltd

Novartis AG

Bristol-Myers Squibb Co

AbbVie Inc

Merck & Co Inc

F. Hoffmann-La Roche Ltd

Oncotherapeutics